Recent Updates
Recently added Catalysts
STAA Positive Sentiment

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: STAAR Surgical has appointed Warren Foust as its new President and CEO, effective August 4, 2026. Foust, who joined the company in April 2023, will also serve on the Board of Directors. This leadership change follows a thorough global search by the Board.

Market Sentiment Analysis

POSITIVE FACTORS

  • Warren Foust brings extensive experience to the role.
  • The appointment is expected to strengthen STAAR's leadership.
  • Foust's previous experience may enhance company growth.

Full Press Release Details

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extensive global search, its Board of Directors (the "Board") has appointed Warren Foust as President and Chief Executive Officer and a new member of the Board of Directors, effective August 4, 2026. Mr. Foust joined STAAR in April 2023 and h

Frequently Asked Questions

Who is the new CEO of STAAR Surgical?

Warren Foust has been appointed as the new CEO of STAAR Surgical.

When will Warren Foust start as CEO?

Warren Foust will officially start as CEO on August 4, 2026.

What is Warren Foust's background?

Warren Foust joined STAAR in April 2023 and has extensive experience.

What role will Foust have on the Board?

Foust will also serve as a member of the Board of Directors.

ShareAdd on Google
Tags: STAA Viatris Investor Conferences Healthcare STAAR Surgical Warren Foust CEO appointment leadership change vision correction
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$164M liquidity · $7M/mo burn
~20 mo
Low dilution risk